Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Overview of attention for article published in New England Journal of Medicine, March 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 10 news outlets
blogs: 2 blogs
twitter: 90 X users
patent: 12 patents
facebook: 7 Facebook pages

wikipedia: 1 Wikipedia page
reddit: 1 Redditor
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources

Readers on

mendeley: 488 Mendeley

So far, Altmetric has seen 106 X posts from 90 X users, with an upper bound of 1,368,803 followers.

Key references (both NEJM): Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab (Ridker et al.): https://t.co/sK30SBEFBU Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients (SPIRE-1 & SPIRE-2; Ridker et al.…

https://t.co/8DG0rJug11

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients | NEJM https://t.co/PuD2qpmKIm

Leaving ACC thinking about what if bococizumab hadn't had anti-drug antibodies. SPIRE-2 trial was enrolling patients w/ LDLc>100mg/dL,and at time trial stopped was already showing 18% reduction in CV death (caveat small numbers). Could have been the …

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 102 additional X posts.